32 years @Pfizer. #Hematology Opinion Leader Liaison, passionately helping to better lives of patients with blood cancer. My opinions are my own. #PFEColleague
#ASH25 US Multiple Myeloma Immunotherapy consortium
We presented 14 orals, 8 posters at ASH!
Now with 25+ sites
Could never have imagined this success when Dr Hansen, Patel and I co-founded this 4+ years ago.
Incredible collaborative effort!! A lot of work goes into this.
Excited to be at #ASH25 where Pfizer is sharing 20+ abstracts in blood cancer across #multiplemyeloma, #leukemia & #lymphoma. Visit booth #1843 to see how we’re advancing science in hematologic malignancies and working to improve outcomes for patients.
WATCH: Binod Dhakal, MD, explores innovative bridging therapies for multiple myeloma, enhancing patient outcomes before CAR T-cell treatment while addressing significant challenges. Check out the full interview: https://t.co/O7elyrWSEX
I love talking to current and former patients.
They keep us grounded, humbled, and remind us why we do what we do and how we can do better.
Today’s #HealthcareUnfiltered is ALL about that as Carol Rausch shares her story.
A must listen for all.
https://t.co/ChYBprLMV9
#weekend_review#MedTwitter#hemonctrainees
1/ Focusing on "chemo-free" regimen for "Ph-ve" B-cell ALL
1. Blinatumomab is better induction or Inotuzumab ozogamicin?
2. Response rate with chemo-free regimen in high risk ALL?
3. Should we intensify CNS prophylaxis with "chemo-free" regimen?👇
By continuing to accelerate advancements in the treatment of #BloodCancer, we’re working to create a world where people with cancer live better and longer lives.. #BloodCancerAwarenessMonth#PFEColleague https://t.co/JmwSUHuiNe
phase Ib/II study of sonrotoclax and dex in RRMM with t (11;14)- ORR 75% at 640 mg with ~70% triple class ref pts! Impressive safety profile with no DLT @EHA_Hematology @MCWCancerCenter #EHA24
Looking forward to serving with such an incredible group on the @HOPArx board!
We are all motivated by our commitment to our patients, team and profession. We like to 😂 too!!
#oncopharm
Come say hi! #HOPA2024
As we recognize International Women’s Day (IWD) and Women’s History Month (WHM), I’m committed to #InspiringInclusion. I’m #PfizerProud to work at a company that values, respects, and includes all people, no matter our backgrounds. #IWD2024#PFEColleague https://t.co/Uet1S0jyeA
#ASH23#mmsm Some more nice figures to use from educational sessions
Key considerations to determine if CAR T-cell therapy is appropriate for a patient with multiple myeloma
A special message of appreciation to the CML patients and families, and gratitude to the research and health care teams who have impacted this disease. #CML#WorldCMLday#PFEColleague https://t.co/yZ40wO4Ttc